Overview: Neutrophil Gelatinase-Associated Lipocalin TestIntroduction: The Neutrophil Gelatinase-Associated Lipocalin Test measures NGAL to diagnose kidney injury, causing reduced urine output or swelling. Following 2023 KDIGO guidelines, it uses biochemistry methods for high specificity, supporting renal screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in biochemistry for patients with suspected acute kidney injury or chronic kidney disease.
Other Names: NGAL Assay, Kidney Injury Biomarker Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic accuracy.
Historical Milestone: NGAL testing began in the 2000s with kidney injury research. Biochemical methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Measures NGAL to diagnose kidney injury, guides treatment, and evaluates patients with reduced urine output or swelling.
Test Parameters: 1. Neutrophil Gelatinase-Associated Lipocalin
Pretest Condition: No fasting required. Collect urine, serum, or plasma. Report history of reduced urine output, swelling, or kidney disease.
Specimen: Urine (sterile container, 5-20 mL), Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 2 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not frozen
Medical History: Document reduced urine output, swelling, fatigue, or history of kidney disease. Include current medications, especially nephrotoxic drugs.
Consent: Written consent required, detailing the tests purpose, kidney injury implications, and risks of sample collection.
Procedural Considerations: Uses biochemistry methods (e.g., ELISA) to measure NGAL in urine, serum, or plasma. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for kidney injury diagnosis.
Factors Affecting Result Accuracy: Contamination, improper sample storage, or low sample volume can affect results. Inflammation may elevate NGAL.
Clinical Significance: Elevated NGAL confirms kidney injury, guiding supportive care or dialysis. Normal levels may require further renal testing.
Specialist Consultation: Consult a nephrologist for result interpretation and treatment planning.
Additional Supporting Tests: Creatinine, BUN, or kidney ultrasound to confirm kidney injury diagnosis.
Test Limitations: Not specific to one type of kidney injury; clinical correlation is needed. Sample quality affects accuracy.
References: KDIGO AKI Guidelines, 2023; Kidney International, Haase M, 2022.
